OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Phase 3 data expected in the second half of 2024
Yesafili, received marketing authorization approval from the European Commission for the European Union
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Subscribe To Our Newsletter & Stay Updated
